Tivic Health Systems Inc. has announced the expansion of its patent portfolio with a new filing for a Vagus Nerve Stimulation (VNS) System. The recently filed patent, No. 63,801,058, aims to enhance the efficacy of non-invasive VNS technology by focusing on the personalization of stimulation parameters and electrode positioning. This development is expected to advance the state-of-the-art in vagus nerve interventions, offering improved therapeutic effects. Tivic's Chief Scientific Officer, Blake Gurfein, emphasized the company's commitment to building a defensible position for its next-generation VNS technology. CEO Jennifer Ernst highlighted the importance of protecting the company's intellectual property as they continue to advance their VNS program.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。